Manuel Ruiz-Borrego

Trop-2 overexpression as a prognostic marker in early triple-negative breast cancer: results from the GEICAM_CIBOMA trial

Federico Rojo, Sara López‐Tarruella, Begoña Bermejo, Laura Torrecillas et autres

Trophoblast cell-surface antigen 2 (Trop-2) is a key therapeutic target in metastatic triple-negative breast cancer (TNBC), yet its prognostic significance in early-stage disease remains poorly defined. We evaluated Trop-2 expression and its clinical impact within a sub-cohort of the phase III GEICAM_CIBOMA …

es, us, br, mx, cl, pe (code pays fourni par la source)

Breastfeeding shapes a unique tumor-immune landscape in pregnancy-associated breast cancer from GEICAM-EMBARCAM study

Regina Peña-Enríquez, Ángel Guerrero-Zotano, Begoña Bermejo, Alejandra Díaz-Chacón et autres

BACKGROUND: Pregnancy-associated breast cancer (PABC) is an aggressive malignancy affecting young women during gestation, lactation, or the post-weaning period. Despite its clinical significance and poor prognosis, how these physiological stages shape tumor biology remains poorly understood. Here, we integrate reproductive context with …

es, us (code pays fourni par la source)

Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial

Olivia Pagani, Samuel M. Niman, Monica Ruggeri, Fedro Alessandro Peccatori et autres

us, ch, it, ps, es, jp, no, nl, ca, fr, ie, be, si, kr, au, de, rs, pt (code pays fourni par la source)

Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial

M Casado Martín, Álvaro Rodríguez-Lescure, Cristina Reboredo, Eveline Chen et autres

PURPOSE: To independently validate that low endocrine transcriptional activity measured by the sensitivity to endocrine therapy (SETER/PR) index in hormone receptor-positive (HR+) breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective-retrospective biomarker study. EXPERIMENTAL DESIGN: We conducted a blinded, …

es, us (code pays fourni par la source)

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial

Ángel Guerrero-Zotano, Miguel Gil‐Gil, Amy Williams, Manuel Ruiz-Borrego et autres

BACKGROUND: Treatment selection in endocrine-resistant HR+ /HER2 - metastatic breast cancer (MBC) remains challenging, and early predictive biomarkers are lacking. Circulating thymidine kinase 1 activity (TKa) is a blood-based proliferation marker suitable for dynamic monitoring. METHODS: This translational study was conducted within …

es, se, us, at (code pays fourni par la source)

Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies

Sonia Servitja, Eva Carrasco, Raquel Andrés, Álvaro Rodríguez-Lescure et autres

PURPOSE: Endocrine therapy (ET) with or without abemaciclib/ribociclib is the current standard for intermediate- and high-risk hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) patients. The NATALEE trial showed that adding 3 years of ribociclib to ET improves the 4-year invasive Disease-Free Survival …

es (code pays fourni par la source)

18F-FDG-PET-guided, pathological complete response-adapted chemotherapy de-escalation in HER2-positive early breast cancer: 5-year outcomes and exploratory ctDNA analyses from the randomized phase 2 PHERGain trial

Antonio Llombart‐Cussac, José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego et autres

es, ch, fr, gb, be, de, it, pt, us (code pays fourni par la source)

UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer

Ana Gil-Torralvo, M. Ángeles Domínguez-Cejudo, Sonia Molina-Pinelo, Carmen Garrigós et autres

BACKGROUND: Pathological complete response (pCR) after neoadjuvant therapy is a robust surrogate marker for long-term outcomes in breast cancer. Despite major advances with targeted therapies, a significant proportion of patients fail to achieve pCR, underscoring the urgent need for reliable biomarkers that …

es (code pays fourni par la source)

Supplementary Data1 from Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2− Highly Proliferative Breast Cancer

Miguel Martín, Ángel L. Guerrero-Zotano, Eva Pérez, Manuel Ruiz-Borrego et autres

Supplementary Material

Data from Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2− Highly Proliferative Breast Cancer

Miguel Martín, Ángel L. Guerrero-Zotano, Eva Pérez, Manuel Ruiz-Borrego et autres

AbstractPurpose: Neoadjuvant chemotherapy is standard for high-risk hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+/HER2−) breast cancer. This study evaluates whether 12 months of letrozole plus abemaciclib could be an alternative. Patients and Methods: The phase II, open-label CARABELA trial …

Real-world effectiveness and safety of Sacituzumab Govitecan in metastatic triple-negative breast cancer: results from the multicenter retrospective observational SACISUR cohort in Southern Spain

Alejandro Falcón-González, Elisenda Llabres-Valentí, Fernando Henao-Carrasco, Rocio Urbano-Cubero et autres

Background: Sacituzumab govitecan (SG) has demonstrated efficacy in metastatic triple-negative breast cancer (mTNBC) in clinical trials, but real-world data from routine clinical practice remains limited. This study aimed to evaluate the effectiveness and safety of SG in mTNBC patients in Southern Spain. …

es, us (code pays fourni par la source)